ABOS Form 3 filed: No beneficial ownership reported by director

Rhea-AI Filing Summary

Acumen Pharmaceuticals (ABOS) filed a Form 3, the initial statement of beneficial ownership under Section 16. The filing identifies the reporting person as a Director and indicates it was filed by one reporting person. The Form 3 states that no securities are beneficially owned. The date of the event requiring the statement is 11/06/2025. A Power of Attorney is included as Exhibit 24.1, and the form is signed by attorney-in-fact Derek Meisner.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Golumbeski George

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2025

3. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Derek Meisner, Attorney-in-Fact	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Acumen Pharmaceuticals (ABOS) file?

A Form 3 initial statement of beneficial ownership under Section 16.

What does the Form 3 for ABOS disclose?

It reports that the Director beneficially owns no securities.

Who filed the ABOS Form 3?

It was filed by one reporting person identified as a Director; the signature is by attorney-in-fact Derek Meisner.

What is the event date on the ABOS Form 3?

The event date is 11/06/2025.

Does the ABOS Form 3 include a Power of Attorney?

Yes, Exhibit 24.1 is a Power of Attorney.